Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma Ads (NQ: ASND )

146.91 USD +3.46 (+2.41%)
Official Closing Price Updated: 5:08 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 239,000
Open 144.66
Bid (Size) 146.44 (1)
Ask (Size) 146.91 (6)
Prev. Close 143.45
Today's Range 136.58 - 146.91
52wk Range 92.00 - 183.98
Shares Outstanding 41,779,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
From GlobeNewswire News Releases

Performance

YTD
-11.23%
-11.23%
1 Month
-2.63%
-2.63%
3 Month
-14.54%
-14.54%
6 Month
+2.64%
+2.64%
1 Year
+13.07%
+13.07%

More News

Read More
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
From PR Newswire
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
From GlobeNewswire News Releases
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
From PR Newswire
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
From Business Wire News Releases
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Planned Board Transition
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.